دورية أكاديمية
أعرض في EDS

Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients.

التفاصيل البيبلوغرافية
العنوان: Hydroxychloroquine decreases Th17-related cytokines in systemic lupus erythematosus and rheumatoid arthritis patients.
المؤلفون: Silva JC; Universidade Federal de Pernambuco, Laboratório de Imunomodulação e Novas Abordagens Terapêuticas, Recife/PE, Brasil., Mariz HA, Rocha LF Jr, Oliveira PS, Dantas AT, Duarte AL, Pitta Ida R, Galdino SL, Pitta MG
المصدر: Clinics (Sao Paulo, Brazil) [Clinics (Sao Paulo)] 2013 Jun; Vol. 68 (6), pp. 766-71.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101244734 Publication Model: Print Cited Medium: Internet ISSN: 1980-5322 (Electronic) Linking ISSN: 18075932 NLM ISO Abbreviation: Clinics (Sao Paulo) Subsets: MEDLINE
أسماء مطبوعة: Publication: 2022- : [New York] : Elsevier
Original Publication: São Paulo, SP : Hospital das Clínicas, Faculty of Medicine, University of São Paulo, [2005]-
مواضيع طبية MeSH: Antimalarials/*pharmacology , Arthritis, Rheumatoid/*blood , Hydroxychloroquine/*pharmacology , Interleukins/*blood , Lupus Erythematosus, Systemic/*blood , Th17 Cells/*drug effects, Adult ; Aged ; Antimalarials/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Case-Control Studies ; Cell Count ; Cells, Cultured ; Enzyme-Linked Immunosorbent Assay ; Female ; Humans ; Hydroxychloroquine/therapeutic use ; Interleukin-17/blood ; Interleukin-6/blood ; Lupus Erythematosus, Systemic/drug therapy ; Middle Aged ; Statistics, Nonparametric ; Th17 Cells/immunology ; Young Adult ; Interleukin-22
مستخلص: Objectives: Hydroxychloroquine is an antimalarial agent that has been used in systemic lupus erythematosus and rheumatoid arthritis treatment for many years. Recently, novel mechanisms of action have been proposed, thereby broadening the therapeutic perspective of this medication. The purpose of this study was to evaluate the immunomodulatory activity of hydroxychloroquine in T helper 17 (Th17) cytokines in healthy individuals and patients.
Methods: Eighteen female patients with systemic lupus erythematosus (mean age 39.0±12.9 years) and 13 female patients with rheumatoid arthritis (mean age 51.5±7.7 years) were recruited from Universidade Federal de Pernambuco-Brazil. The patients were included after fulfilling four classification criteria for systemic lupus erythematosus or rheumatoid arthritis from the American College of Rheumatology. After being stimulated with phorbol 12-myristate 13-acetate and ionomycin in the absence or presence of different concentrations of hydroxychloroquine, the interleukin 6, 17 and 22 levels were quantified with an enzyme-linked immunosorbent assay in culture supernatants of peripheral blood mononuclear cells from healthy individuals and patients.
Results: We demonstrated that in peripheral blood mononuclear cells from healthy volunteers and in systemic lupus erythematosus and rheumatoid arthritis patients, there was a significant reduction in the IL-6, IL-17 and IL-22 supernatant levels after adding hydroxychloroquine. CONCLUSIONS Our in vitro results demonstrated that hydroxychloroquine inhibits IL-6, IL-17 and IL-22 production and contributes to a better understanding of the mechanism of action of this medication.
References: Br J Dermatol. 2008 Nov;159(5):1124-30. (PMID: 18764842)
Lupus. 2002;11(6):356-61. (PMID: 12139373)
Proc Natl Acad Sci U S A. 1978 Jul;75(7):3327-31. (PMID: 28524)
Arthritis Rheum. 2009 May;60(5):1472-83. (PMID: 19404966)
J Rheumatol. 2012 Jul;39(7):1320-5. (PMID: 22589261)
Arthritis Rheum. 1999 May;42(5):963-70. (PMID: 10323452)
J Exp Med. 2007 Nov 26;204(12):2803-12. (PMID: 18025126)
J Rheumatol. 1997 Jan;24(1):55-60. (PMID: 9002011)
Arthritis Rheum. 1982 Nov;25(11):1271-7. (PMID: 7138600)
Nat Clin Pract Rheumatol. 2006 Sep;2(9):458-9. (PMID: 16951696)
Am J Pathol. 2005 Jul;167(1):141-9. (PMID: 15972960)
Curr Opin Rheumatol. 2010 Sep;22(5):499-503. (PMID: 20592603)
Curr Opin Rheumatol. 2011 May;23(3):278-81. (PMID: 21448012)
Nat Rev Rheumatol. 2012 Sep;8(9):522-33. (PMID: 22801982)
Proc Natl Acad Sci U S A. 1982 Jan;79(1):175-8. (PMID: 6798568)
Chin Med J (Engl). 2003 Apr;116(4):543-8. (PMID: 12875719)
N Engl J Med. 2003 Dec 18;349(25):2399-406. (PMID: 14681505)
JAMA. 2007 Jul 11;298(2):187-93. (PMID: 17622600)
Ann Rheum Dis. 2007 Sep;66(9):1168-72. (PMID: 17389655)
J Exp Med. 2005 Oct 17;202(8):1131-9. (PMID: 16230478)
Clin Exp Immunol. 2009 Aug;157(2):209-15. (PMID: 19604260)
Clin Rev Allergy Immunol. 2012 Apr;42(2):145-53. (PMID: 21221847)
Arthritis Res Ther. 2010;12(2):R53. (PMID: 20334681)
Rheumatology (Oxford). 2009 Dec;48(12):1491-7. (PMID: 19773408)
Ann Intern Med. 1993 Dec 1;119(11):1067-71. (PMID: 8239224)
Arthritis Rheum. 1988 Mar;31(3):315-24. (PMID: 3358796)
Am J Pathol. 2012 Jul;181(1):8-18. (PMID: 22640807)
Lupus. 2006;15(9):577-83. (PMID: 17080912)
Lupus. 2000;9(8):589-93. (PMID: 11035433)
N Engl J Med. 1991 Jan 17;324(3):150-4. (PMID: 1984192)
Lupus. 1996 Jun;5 Suppl 1:S16-22. (PMID: 8803905)
Immunology. 2002 Jan;105(1):83-91. (PMID: 11849318)
J Rheumatol. 1994 Aug;21(8):1457-62. (PMID: 7983646)
Lupus. 1996 Jun;5(3):237-41. (PMID: 8803897)
المشرفين على المادة: 0 (Antimalarials)
0 (Interleukin-17)
0 (Interleukin-6)
0 (Interleukins)
4QWG6N8QKH (Hydroxychloroquine)
تواريخ الأحداث: Date Created: 20130620 Date Completed: 20140320 Latest Revision: 20231213
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC3674253
DOI: 10.6061/clinics/2013(06)07
PMID: 23778483
قاعدة البيانات: MEDLINE
الوصف
تدمد:1980-5322
DOI:10.6061/clinics/2013(06)07